Cardioprotection—Time to Take Into Account Clinical Complexity: The Case of Antiplatelet Agents François RoubilleJean-Claude Tardif EDITORIAL 27 January 2013 Pages: 105 - 107
Two Classes of Anti-Platelet Drugs Reduce Anatomical Infarct Size in Monkey Hearts Xi-Ming YangYanping LiuMichael V. Cohen ORIGINAL ARTICLE 15 January 2013 Pages: 109 - 115
Asialoerythropoietin Exerts Stronger Angiogenic Activity than Erythropoietin Via its Binding Affinity to Tissue Takao YanagawaKen TobaYoshifusa Aizawa ORIGINAL ARTICLE 13 January 2013 Pages: 117 - 124
Liposomal Amiodarone Augments Anti-arrhythmic Effects and Reduces Hemodynamic Adverse Effects in an Ischemia/Reperfusion Rat Model Hiroyuki TakahamaHirokazu ShigematsuTetsuo Minamino ORIGINAL ARTICLE 24 January 2013 Pages: 125 - 132
It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems Osamu TsukamotoMasafumi Kitakaze OriginalPaper 07 December 2011 Pages: 133 - 138
Chymase Inhibition and Cardiovascular Protection Hideaki TojoHidenori Urata REVIEW ARTICLE 07 March 2013 Pages: 139 - 143
Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest? Michel AziziJoël Ménard Review Article 06 March 2012 Pages: 145 - 153
ARB and Cardioprotection Hiroshi AkazawaChizuru YabumotoIssei Komuro OriginalPaper 27 April 2012 Pages: 155 - 160
Parathyroid Hormone, A Crucial Mediator of Pathologic Cardiac Remodeling in Aldosteronism Michael R. RutledgeVictor FarahKarl T. Weber OriginalPaper 29 February 2012 Pages: 161 - 170
RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials Thomas G. von LuederHenry Krum Review Article 07 December 2012 Pages: 171 - 179
Ataluren: Time for a ‘No-Nonsense’ Approach to Heart Diseases John A. Loudon LETTER TO THE EDITOR 06 January 2013 Pages: 181 - 182
